• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Scottish Health Technologies Group (SHTG) Open, laparoscopic and robot-assisted laparoscopic radical prostatectomy for localised prostate cancer.
2012     Scottish Health Technologies Group (SHTG) What implications does the organisation of vascular services have for rates of amputation?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and outcome in elective carotid endarterectomy surgery?
2012     Scottish Health Technologies Group (SHTG) Is there a difference in operative mortality between endovascular aneurysm repair and open surgery in elective abdominal aortic aneurysm?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and operative mortality for surgical repair (open and endovascular) of unruptured and ruptured abdominal aortic aneurysms?
2012     Scottish Health Technologies Group (SHTG) In patients with severe medically refractory gastroparesis (such as those requiring nutritional support), how effective and cost effective is gastric electrical stimulation (EnterraTM device) in reducing symptoms, reducing requirement for nutritional support or hospitalisation and improving quality of life, when compared with medical or alternative surgical management?
2012     Scottish Health Technologies Group (SHTG) What is the relative clinical effectiveness, cost effectiveness and safety of different bariatric surgery techniques (gastric bypass, gastric banding and sleeve gastrectomy)?
2012     Scottish Health Technologies Group (SHTG) In radiotherapy for cancer, what are the patient safety benefits and resource implications of the various in vivo methods of dosimetry to check received radiation dose, compared with pretreatment verification only?
2012     Scottish Health Technologies Group (SHTG) Is it clinically and cost effective to perform second-eye cataract surgery in the absence of other ocular co-morbidities in patients who have already had first-eye surgery?
2012     Scottish Health Technologies Group (SHTG) What is the impact of using thresholds (both for referral and surgery) for first-eye cataract surgery on the delivery of the cataract service and the resources associated with it?
2012     Scottish Health Technologies Group (SHTG) The clinical and cost-effectiveness of radiofrequency ablation for lung cancer
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of temporal artery thermometers compared with infrared in-ear thermometers for temperature measurement in routine clinical practice?
2013     Scottish Health Technologies Group (SHTG) Are silver dressings clinically effective and cost effective for the healing of infected wounds and the prevention of wound infection relative to other types of dressing?
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with sarcoidosis yield clinical and economic benefits?
2013     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of dynamic elastomeric fabric orthoses (DEFOs) for cerebral palsy?
2013     Scottish Health Technologies Group (SHTG) Can wrist splints or steroid injections reduce the need for decompression surgery in carpal tunnel syndrome?
2013     Scottish Health Technologies Group (SHTG) What is the sensitivity and specificity of PET/CT compared with other diagnostic imaging modalities in determining the cause of pyrexia of unknown origin (PUO)? What is the clinical and cost effectiveness of PET/CT as a first-line investigation in patients with PUO?
2013     Scottish Health Technologies Group (SHTG) What is the clinical effectiveness, cost effectiveness and implications for safety of assessing anti-tumour necrosis factor (TNF)α drug levels and antibodies in children with moderate to severe inflammatory bowel disease compared with existing clinical strategies in use in NHS Scotland?
2013     Scottish Health Technologies Group (SHTG) PET/CT for the inversitgation of paraneoplastic syndromes (PNS)
2013     Scottish Health Technologies Group (SHTG) Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious, and cost effective? (update of EN 27)
2014     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of treatment with renal denervation for patients with resistant hypertension?
2013     Scottish Health Technologies Group (SHTG) What is the evidence for the clinical and cost effectiveness of major trauma centres as the core component of a trauma service, compared with standard care for adults with major trauma?
2013     Scottish Health Technologies Group (SHTG) Is cone beam computed tomography (CBCT) clinically effective, cost-effective and safe compared with standard extraoral and intraoral radiography in the diagnosis of hard tissue pathology in routine dental practice?
2013     Scottish Health Technologies Group (SHTG) What approaches have been taken and efforts made to ensure public involvement in decision making relating to potential disinvestment in healthcare interventions and technologies?
2014     Scottish Health Technologies Group (SHTG) In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies?
2020     Scottish Health Technologies Group (SHTG) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2024     Scottish Health Technologies Group (SHTG) Green theatres
2021     Scottish Health Technologies Group (SHTG) Elective surgery using mesh to repair primary or incisional hernias in adults
2021     Scottish Health Technologies Group (SHTG) A Unique Device Identifier (UDI) system for recording, identifying and recalling medical devices
2015     Scottish Health Technologies Group (SHTG) Magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids
2023     Scottish Health Technologies Group (SHTG) Priorities for the north imaging alliance
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     Scottish Health Technologies Group (SHTG) Digital prevention programme for people at risk of type 2 diabetes
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021     Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021     Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021     Scottish Medicines Consortium (SMC) Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021     Scottish Medicines Consortium (SMC) Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Nucleoplasty for treating disk herniation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 12: Clinical strategies for smoking cessation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 11: Positron Emission Tomography (PET) in the diagnosis, staging and restaging of patients with colorectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 10: Rituximab in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 09: Statins for the prevention of cardiovascular events]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 08: Drug-eluting stents and bare-metal stents in the treatment of coronary artery disease]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 07: Deferasirox for the treatment of iron overload
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of natriuretic peptides for diagnosing cardiac insufficiency in patients with acute dyspnea]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant melanoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of esophageal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant lymphoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Alteplase (rt-PA) in the cerebral vascular ischemic accident]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of breast cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of colon and rectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of polyglycolic polymerized matrix artery graft]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of head and neck cancers]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of radiofrequency ablation in the surgical treatment of atrial fibrillation]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of basal action recombinant insulin, analogous to human insulin, (glargine and determir) for treating type 1 diabetes mellitus]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of paliperidone for treating schizophrenia]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximabe in treating B-cell non-hodgkin's lymphoma, low-grade CD 20]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of the artery protection system Embol-X]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of lithium dilution systems for monitoring cardiac output: comparison with available alternatives]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Bortezomib in treating refractory multiple myeloma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of everolimus to prevent renal transplant rejection]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for Dukes'C colorectal cancer (stage III)]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for metastatic breast cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Avastin in ophthalmology]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximab for rheumatoid arthritis]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of alpha thyrotropin for diagnosis and treatment of thyroid cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of a disposable multi-dose injection pen pre-filled with human growth hormone (somatropin) solution for injection (Norditropin Nordilet)]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 06: Angiogenesis inhibitors for the treatment of age-related macular degeneration
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 05: Bariatric surgery for the treatment of morbid obesity
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 04: Multiple-detector computed tomography for the diagnosis of coronary artery disease
2007     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 02: Drotecogin alfa for the treatment of serious sepsis
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 01: Entecavir for the treatment of chronic hepatitis-B
2004     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [18-FDG positron emission tomography in oncology: HTA reports by international HTA agencies]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for treating lumbago]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for carpal tunnel syndrome]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for headache]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for lateral epicondylitis]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Ferrara corneal ring for treating keratoconus]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new electrophysiology catheters]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) Haemodynamic catheters
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Intersomatic fusion techniques of individual or two-level intervertebral for treating degenerative disease of cervical disks]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drotrecogin alfa in the treatment of severe sepsis]